Home › Chronic Lymphocytic Leukemia › Tennessee › Nashville
Chronic Lymphocytic Leukemia clinical trials in Nashville, TN
13 studies for Chronic Lymphocytic Leukemia are looking for participants at sites in and around Nashville (within about 30 miles). Open a study to see who can join and how to contact the study team.
A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
RecruitingPhase 1/2
- Tennessee Oncology, Pllc Nashville, Nashville
A Study to Evaluate the Safety and Efficacy of Tacabrutideg (BGB-16673) Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
RecruitingPhase 3
- Tennessee Oncology, Pllc Nashville, Nashville
A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)
RecruitingPhase 3
- Tennessee Oncology, Nashville
A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)
RecruitingPhase 3
- Tennessee Oncology, PLLC - Elliston Place Plaza Medical Oncology & Hematology ( Site 0031), Nashville
A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201)
RecruitingPhase 2
- SCRI Oncology Partners, Nashville
Study of NX-5948 Versus Pirtobrutinib in R/R CLL/SLL
RecruitingPhase 3
- SCRI Oncology Partners, Nashville
Study of NX-5948 in Combination With Other Agents in Adults With B-cell Malignancies
RecruitingPhase 1/2
- SCRI Oncology Partners, Nashville
A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
RecruitingPhase 3
- Sarah Cannon Research Institute SCRI, Nashville
Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
RecruitingPhase 1/2
- TriStar BMT, Nashville
A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies
RecruitingPhase 1
- Tennessee Oncology, Nashville
A Study of (LY3527727) Pirtobrutinib in Participants With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma
RecruitingPhase 4
- Tennessee Oncology, Nashville
A Master Protocol to Evaluate the Long-Term Safety of (LY3527727) Pirtobrutinib
RecruitingPhase 4
- Tennessee Oncology, Nashville
HPC Offered for PRESERVE Expansion
RecruitingObservational study
- Tristar Centennial Medical Center, Nashville
Chronic Lymphocytic Leukemia trials in other cities
- Boston, MA32 studies
- Columbus, OH29 studies
- Durham, NC27 studies
- Washington, DC22 studies
- Seattle, WA21 studies
- Rochester, MN19 studies
- New York City, NY18 studies
- Houston, TX17 studies
- Baldwin Park, CA16 studies
- Milwaukee, WI14 studies
- Cincinnati, OH14 studies
- Chicago, IL14 studies
Other studies in Nashville
- Non-Small Cell Lung Cancer96 studies
- Breast Cancer79 studies
- Metastatic Cancer69 studies
- Colorectal Cancer68 studies
- Cancer (all types)64 studies
- Ovarian Cancer48 studies
- Prostate Cancer43 studies
- Pancreatic Cancer40 studies
- Lung Cancer40 studies
- Head and Neck Squamous Cell Carcinoma39 studies
- Endometrial Cancer37 studies
- Melanoma32 studies
From ClinicalTrials.gov, data retrieved Sep 29, 2026. Each study sets its own eligibility; the study team decides who can join.